BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Saturday, April 20, 2024
See today's BioWorld
Home
» Awaiting Genasense Decision, Genta Gets $16M In Stock Sale
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Awaiting Genasense Decision, Genta Gets $16M In Stock Sale
Sep. 21, 2006
By
Jennifer Boggs
No Comments
The pinchpenny public market is pushing more firms to take the route of Solexa Inc., which gained a pledge for $75 million in a stock equity financing from busy Azimuth Opportunity Ltd. (BioWorld Today)
BioWorld